Skip to content
Inciteful Med
Resources About us Ask a Question

Why You Need Dental Clearance Before Zometa & Xgeva

Published: | Updated:

Dental clearance is required before starting Zometa or Xgeva for multiple myeloma to prevent a severe jawbone complication called MRONJ. You must complete invasive dental work like tooth extractions and allow your mouth to fully heal before beginning these infusions.

Key Takeaways

  • • Dental clearance before starting Zometa or Xgeva significantly lowers the risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ).
  • • Invasive procedures like tooth extractions or dental implants must be completed and fully healed before beginning bone-strengthening infusions.
  • • Waiting for your mouth to heal delays your bone infusions, but it generally does not delay your primary multiple myeloma treatments like chemotherapy.
  • • Routine dental care, including cleanings, fillings, and crowns, remains safe and is highly encouraged while actively receiving Zometa or Xgeva.
  • • You should never temporarily stop taking these medications for a dental procedure without strict medical supervision from your oncologist.

Before starting bone-strengthening infusions like Zometa (zoledronic acid) or Xgeva (denosumab) for multiple myeloma, your oncologist will require you to get “dental clearance.” This extra step is necessary to prevent a rare but serious side effect called Medication-Related Osteonecrosis of the Jaw (MRONJ), often just called ONJ [1][2].

By completing any major dental work and allowing your mouth to heal before you start these specific medications, you drastically lower your risk of developing this complication [3][4]. Fortunately, when proper dental screening guidelines are followed, the absolute risk of developing ONJ remains quite low [5].

Important Note: Waiting for dental clearance generally only delays your Zometa or Xgeva infusions. Your primary multiple myeloma treatments—such as chemotherapy, targeted therapies, or steroids—can usually begin right away without waiting for your jaw to heal.

What is Osteonecrosis of the Jaw (ONJ)?

Osteonecrosis translates to “bone death.” MRONJ occurs when a section of the jawbone loses its blood supply, dies, and becomes exposed through the gums [1]. It is a severe condition that can cause pain, swelling, chronic infection, and difficulty eating [6][7].

Early warning signs to watch for include loose teeth, sudden gum infections, or a feeling of numbness or heaviness in the jaw [7][8]. Because it can take months to heal and sometimes requires surgery, preventing the damage from happening in the first place is the most effective strategy [9][10].

Why Do Bone-Strengthening Infusions Cause ONJ?

Multiple myeloma frequently attacks the bones, causing them to thin, weaken, and fracture. To protect your skeleton, doctors prescribe high-dose medications like Zometa and Xgeva [11][12]. These drugs work by shutting down osteoclasts, the specific cells that normally break down old bone [13].

While stopping bone breakdown protects your spine and hips from myeloma damage, it creates a unique problem in your jaw. Your jawbone is under constant stress from chewing and is exposed to the bacteria in your mouth. Normally, your jaw heals tiny microcracks constantly [13]. However, Zometa and Xgeva slow down this repair process [14]. If you have a tooth pulled or bone surgery while on these drugs, the jawbone struggles to heal the wound, leaving it vulnerable to infection and tissue death [15][16].

Because multiple myeloma patients receive these medications at much higher doses and more frequently than people treating non-cancer conditions like osteoporosis, the risk of ONJ is significantly higher [17][18].

What to Expect During Your Dental Clearance

When you visit your dentist for clearance, they are looking for any issues that might require invasive dental work in the near future. The goal is to proactively fix problems now, avoiding surgery while you are actively receiving infusions [5][15]. It is highly recommended that you ask your dentist and oncologist to communicate directly about your treatment plan [19].

Your dentist will focus on:

  • Invasive Procedures: If you need teeth pulled (extractions), dental implants placed, or deep gum surgery, these must be done before starting your bone-strengthening infusions [3][20].
  • Healing Time: You cannot start Zometa or Xgeva the day after a tooth is pulled. The gums and bone must have enough time to heal—typically 3 to 4 weeks, or until the gums have fully closed over the extraction site [20][16].
  • Active Infections: Any active gum disease or root infections must be treated to prevent them from flaring up later [21][22].
  • Ill-Fitting Dentures: Because dentures that rub against the gums can create sores that expose the jawbone, ensuring your dentures or partials fit perfectly is a crucial part of your clearance exam [15][3].

Dental Care After You Start Treatment

Once your mouth is healed and you begin Zometa or Xgeva, ongoing oral care is critical to preventing ONJ [23][24].

  • Routine Care is Safe: Non-invasive procedures like regular cleanings, simple fillings, and crowns are completely safe and highly encouraged [25][26]. Keeping your teeth clean prevents decay that might lead to an extraction down the line.
  • Tell Every Dentist: Ensure any dentist who treats you knows you are taking a high-dose bone-modifying agent for cancer [27].
  • Avoid “Drug Holidays”: It might seem logical to just pause your medication if you need a tooth pulled later, but this is not recommended without strict medical supervision. Zometa binds directly to your bones and stays embedded there for years, meaning a brief pause won’t lower your ONJ risk [28][29]. Xgeva leaves the body more quickly, but stopping it suddenly can cause a dangerous “rebound” effect leading to rapid bone breakdown and spinal fractures [30][31].

By understanding the “why” behind the extra dentist visit, you can confidently navigate this step and safely protect your bones from multiple myeloma.

Frequently Asked Questions

Why do I need to see a dentist before starting Zometa or Xgeva?
Seeing a dentist before starting these medications is necessary to complete any major dental work and allow your mouth to heal. This drastically lowers your risk of developing a serious complication called Medication-Related Osteonecrosis of the Jaw (MRONJ).
Will waiting for dental clearance delay my multiple myeloma treatment?
Waiting for dental clearance generally only delays your Zometa or Xgeva infusions. Your primary multiple myeloma treatments, such as chemotherapy or targeted therapies, can usually begin right away without waiting for your jaw to heal.
Can I have a tooth pulled while taking Zometa or Xgeva?
Having a tooth pulled while on these medications is highly risky because the drugs slow down your jawbone's ability to heal. If you unexpectedly need an extraction, your oncologist and dentist must closely coordinate your care to minimize the risk of jaw damage.
Is it safe to get regular dental cleanings during my multiple myeloma treatment?
Yes, routine dental care like regular cleanings, simple fillings, and crowns are completely safe and highly encouraged. Keeping your teeth clean prevents decay that might lead to a dangerous tooth extraction later on.
What are the warning signs of osteonecrosis of the jaw (ONJ)?
Early warning signs of ONJ include loose teeth, sudden gum infections, or a feeling of numbness or heaviness in the jaw. If you experience any of these symptoms or have poorly fitting dentures, you should alert your dentist and oncologist immediately.

Questions for Your Doctor

  • • Will waiting for dental clearance and healing delay the start of my primary anti-cancer treatments (like chemotherapy or targeted therapy)?
  • • Do you have a specific dental clearance form my dentist needs to fill out, and how should your offices communicate?
  • • If I unexpectedly need a tooth pulled after I have already started Zometa or Xgeva, what safety protocols will you and my dentist put in place?
  • • Which specific bone-strengthening infusion are you recommending for me, and how does that choice impact my long-term dental care?

Questions for You

  • • Do I have any loose teeth, persistent gum pain, or poorly fitting dentures that I need to bring to my dentist's attention immediately?
  • • When was my last comprehensive dental exam, and do I have any unfinished dental work (like a pending root canal or implant)?
  • • How can I improve my daily oral hygiene routine at home to ensure my teeth and gums stay as healthy as possible during cancer treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ).

    Kishimoto H, Noguchi K, Takaoka K

    The Japanese dental science review 2019; (55(1)):95-102 doi:10.1016/j.jdsr.2018.09.002.

    PMID: 31193410
  2. 2

    MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.

    Yarom N, Van Poznak CH, Epstein JB, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(8)):547 doi:10.1007/s00520-024-08687-w.

    PMID: 39048887
  3. 3

    The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients.

    Lasky S, Moshal T, Shakoori P, et al.

    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2024; (82(10)):1285-1294 doi:10.1016/j.joms.2024.06.162.

    PMID: 38950582
  4. 4

    Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.

    Drudge-Coates L, Van den Wyngaert T, Schiødt M, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2020; (28(9)):4019-4029 doi:10.1007/s00520-020-05440-x.

    PMID: 32307659
  5. 5

    Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma - a longitudinal cohort study.

    Olofsson R, Korytowska M, Almhöjd U, et al.

    BMC oral health 2024; (24(1)):184 doi:10.1186/s12903-024-03943-1.

    PMID: 38317122
  6. 6

    [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].

    Takaoka K, Kishimoto H

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 2019; (153(1)):22-27 doi:10.1254/fpj.153.22.

    PMID: 30643088
  7. 7

    Low-Intensity Pulsed Ultrasound Prevents Development of Bisphosphonate-Related Osteonecrosis of the Jaw-Like Pathophysiology in a Rat Model.

    Hidaka K, Mikuni-Takagaki Y, Wada-Takahashi S, et al.

    Ultrasound in medicine & biology 2019; (45(7)):1721-1732 doi:10.1016/j.ultrasmedbio.2019.02.015.

    PMID: 31006496
  8. 8

    Preoperative Assessment of Medication-Related Osteonecrosis of the Jaw Using [18F]fluoride Positron Emission Tomography (PET)/CT and [18F]fluorodeoxyglucose PET/MRI in Correlation with Histomorphometry and Micro-CT-A Prospective Comparative Study.

    Reinert CP, Pfannenberg C, Gückel B, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(4)) doi:10.3390/diagnostics14040428.

    PMID: 38396467
  9. 9

    MASCC/ISOO Clinical Practice Statement: imaging and clinical laboratory tests in the diagnosis and management of medication-related osteonecrosis of the jaw.

    Yarom N, Abdalla-Aslan R, Migliorati C, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(10)):852 doi:10.1007/s00520-025-09809-8.

    PMID: 40944737
  10. 10

    Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.

    Kajizono M, Sada H, Sugiura Y, et al.

    Biological & pharmaceutical bulletin 2015; (38(12)):1850-5 doi:10.1248/bpb.b15-00385.

    PMID: 26632176
  11. 11

    Weight-Based Bisphosphonate Administration for Multiple Myeloma Patients and the Risks of Skeletal Complications.

    Bahk JH, Jo WL, Kwon SY, et al.

    Journal of clinical medicine 2023; (12(4)) doi:10.3390/jcm12041637.

    PMID: 36836169
  12. 12

    A Patient with a History of Multiple Myeloma Presents for the Evaluation of Oral Lesion and Burning Sensation of the Mouth.

    Kim IH, Hong WW, Oak S, et al.

    Dental clinics of North America 2023; (67(4)):657-661 doi:10.1016/j.cden.2023.05.014.

    PMID: 37714618
  13. 13

    Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw.

    Elsayed R, Kurago Z, Cutler CW, et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2020; (34(2)):2595-2608 doi:10.1096/fj.201901819RR.

    PMID: 31919918
  14. 14

    Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.

    Bassan Marinho Maciel G, Marinho Maciel R, Linhares Ferrazzo K, Cademartori Danesi C

    Journal of molecular medicine (Berlin, Germany) 2024; (102(3)):353-364 doi:10.1007/s00109-024-02425-9.

    PMID: 38302741
  15. 15

    Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

    Hasegawa T, Hayashida S, Kondo E, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019; (30(1)):231-239 doi:10.1007/s00198-018-4746-8.

    PMID: 30406309
  16. 16

    Bisphosphonates and Their Connection to Dental Procedures: Exploring Bisphosphonate-Related Osteonecrosis of the Jaws.

    Lee ES, Tsai MC, Lee JX, et al.

    Cancers 2023; (15(22)) doi:10.3390/cancers15225366.

    PMID: 38001626
  17. 17

    The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.

    Dodson TB

    Oral and maxillofacial surgery clinics of North America 2015; (27(4)):509-16.

    PMID: 26362367
  18. 18

    Emerging antiresorptive medications and their potential implications for dental surgeries.

    Aminoshariae A, Donaldson M, Horan M, et al.

    Journal of the American Dental Association (1939) 2022; (153(7)):649-658 doi:10.1016/j.adaj.2021.12.008.

    PMID: 35277242
  19. 19

    Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.

    Acharya S, Patil V, Ravindranath V, et al.

    Journal of medicine and life 2022; (15(3)):368-373 doi:10.25122/jml-2021-0085.

    PMID: 35449990
  20. 20

    Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.

    Nicolatou-Galitis O, Schiødt M, Mendes RA, et al.

    Oral surgery, oral medicine, oral pathology and oral radiology 2019; (127(2)):117-135 doi:10.1016/j.oooo.2018.09.008.

    PMID: 30393090
  21. 21

    Untreated Apical Periodontitis and the Risk of Medication-related Osteonecrosis of the Jaws (MRONJ): A Systematic Review with Mechanistic Insights from Preclinical Studies.

    Mota ME, Silva Lascane NA, Gimenez T, et al.

    Journal of endodontics 2026; (52(3)):359-375 doi:10.1016/j.joen.2025.12.002.

    PMID: 41390055
  22. 22

    Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.

    Soutome S, Otsuru M, Hayashida S, et al.

    Scientific reports 2021; (11(1)):17226 doi:10.1038/s41598-021-96480-8.

    PMID: 34446755
  23. 23

    Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States.

    Giri S, Zhu W, Wang R, et al.

    Cancer 2019; (125(22)):4084-4095 doi:10.1002/cncr.32428.

    PMID: 31381151
  24. 24

    Monoclonal Antibodies and Osteonecrosis of the Jaw: A Systematic Review of Risk, Incidence, and Clinical Management in Dentistry.

    Dipalma G, Inchingolo AD, Guglielmo M, et al.

    International journal of dentistry 2025; (2025()):2557594 doi:10.1155/ijod/2557594.

    PMID: 40917557
  25. 25

    Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients.

    Kemp APT, Ferreira VHC, Mobile RZ, et al.

    Brazilian journal of otorhinolaryngology 2022; (88(5)):683-690 doi:10.1016/j.bjorl.2020.09.010.

    PMID: 33189595
  26. 26

    Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India.

    Sankar PS, Thilak SA, Nayak P, et al.

    Contemporary clinical dentistry 2018; (9(1)):35-40 doi:10.4103/ccd.ccd_696_17.

    PMID: 29599581
  27. 27

    Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.

    Marcianò A, Guzzo GM, Peditto M, et al.

    International journal of environmental research and public health 2020; (17(24)) doi:10.3390/ijerph17249509.

    PMID: 33353034
  28. 28

    Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?.

    Sidhu HK

    Dental update 2015; (42(5)):436-8, 440 doi:10.12968/denu.2015.42.5.436.

    PMID: 26964445
  29. 29

    A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

    Hasegawa T, Kawakita A, Ueda N, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017; (28(8)):2465-2473 doi:10.1007/s00198-017-4063-7.

    PMID: 28451732
  30. 30

    Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.

    Cummings SR, Ferrari S, Eastell R, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(2)):190-198 doi:10.1002/jbmr.3337.

    PMID: 29105841
  31. 31

    Hypercalcemia of Malignancy and Medication-Related Osteonecrosis of the Jaw Following Denosumab Discontinuation in Metastatic Breast Cancer: A Case Report.

    Shazley O, Orr C

    Cureus 2025; (17(8)):e91082 doi:10.7759/cureus.91082.

    PMID: 41018442

This page explains the importance of dental clearance before bone-strengthening treatments for educational purposes. Always consult your oncologist and dentist before making any decisions about your dental care or multiple myeloma treatment.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.